Abstract Brief Communication
IntroductIon
Fluoroquinolones (FQs) are broad-spectrum antimicrobial agents used for the treatment of a wide range of community-acquired and nosocomial infections. FQs inhibit deoxyribonucleic acid (DNA) gyrase and topoisomerase IV activities. Soon its discovery, widespread use of this agent has resulted in the emergence of FQ resistance. Mechanisms of resistance to quinolones include alterations in DNA gyrase and topoisomerase IV (quinolone resistance determining region [QRDR] ) and decreased intracellular accumulation of the antimicrobial agent due to modifications of efflux pump activity. The primary target of FQs in Gram-negative bacteria is DNA gyrase, a type II topoisomerase required for DNA replication and transcription. [1] DNA gyrase, which is composed of two A subunits and two B subunits, is encoded by gyrA and gyrB genes, and topoisomerase IV is a tetrameric enzyme composed of two ParC and ParE subunits, encoded by parC and parE genes, respectively. Plasmid-mediated quinolone-resistant mechanisms such as qnr, aac (6') 1b-cr and qepA confer low levels of resistance but provide a favourable background in which selection of additional chromosomally encoded quinolone-resistant mechanisms may occur. [2] In Enterobacteriaceae, resistance to FQs has been shown to be associated most frequently with alterations in gyrA. [3] Resistance to FQs is a result of a combination of mechanisms acting either singly or in combination to produce the resistance phenotype. Point mutations within DNA gyrase (gyrA and gyrB genes) cause a reduction in the affinity of the enzyme for FQs and decrease the susceptibility of the organisms to FQs. Mutations at Ser83 and Asp87 codons of GyrA subunit and Ser80 and Glu84 codons of ParC subunit have been commonly reported in FQ-resistant Escherichia coli isolates worldwide. [4] Thus, the current study was undertaken to investigate and detect the mutations in gyrA and parC responsible for quinolone resistance among clinical isolates of E. coli.
matErIals and mEtHods

Bacterial strain
A total of 96 consecutive nonduplicate clinical isolates of quinolone-resistant E. coli were collected from a tertiary care hospital of North-east India, during March 2015 to August 2015, which were resistant to at least one of the quinolone antibiotics tested. Of these cases of quinolone-resistant E. coli infections, 49 were diagnosed with urinary tract infection (UTI), 26 with gastrointestinal tract infection and 21 with wound infection. All of them were isolated from inpatients admitted to surgery, obstetrics and gynaecology and medicine wards of the hospital.
Screening of quinolone resistance
Screening was done on Mueller-Hinton agar (HiMedia, Mumbai, India) plate by Kirby-Bauer disc diffusion method and interpreted as per the Clinical Laboratory Standard Institute (CLSI) recommendations. The antibiotics tested were nalidixic acid (30 μg), norfloxacin (10 μg), ciprofloxacin (5 μg), ofloxacin (5 μg), gemifloxacin (5 μg), sparfloxacin (5 μg), levofloxacin (5 μg), gatifloxacin (5 μg) and lomefloxacin (10 μg) (HiMedia, Mumbai, India).
Minimum inhibitory concentration (MIC) was done for norfloxacin, ciprofloxacin, ofloxacin and levofloxacin by agar dilution method. The quality control strain used for was E. coli ATCC 25922. Results were interpreted as per the CLSI guidelines 2014.
Antibiotic susceptibility testing of quinolone-resistant isolates
Susceptibility was done by disc diffusion method for the following antibiotics: ampicillin (10 μg), cefotaxime (30 μg), ceftriaxone (30 μg), ceftazidime (30 μg), imipenem (10 μg), co-trimoxazole (25 μg), gentamicin (10 μg) and amikacin (30 μg) (HiMedia, Mumbai, India). The results were interpreted as per the CLSI guidelines 2014.
Detection of acquired quinolone-resistant determinants
To detect the presence of FQ-resistant determinants genes, polymerase chain reaction (PCR) assay was performed for the detection of qnrA, [5] qnrB, [5] qnrC, [5] qnrD, [6] qnrS [5] and aac (6')-Ib-cr. [7] Reactions were run under the following conditions; initial denaturation at 95°C for 2 min; 35 cycles of 95°C for 50 s, 53°C for 40 s and 72°C for 1.20 min and a final extension at 72°C for 5 min. The amplified PCR products were resolved by electrophoresis in 1% agarose gel and visualised after staining with ethidium bromide.
Typing of isolates
Typing of isolates was done by enterobacterial repetitive intergenic sequence (ERIC)-PCR to assess clonal relationships. Each single reaction mixture (25 μl) contained 1 μl (10 ng) of DNA suspension, 15 pmol of each primer, 12.5 μl of 2X GoTaq Green Master Mix (Promega, Madison, USA) and nuclease-free water is added to make a volume of 25 μl. The reaction condition and primers were used as described previously. [8] Amplification of quinolont-resistance determining regions PCR was performed to amplify the QRDRs of gyrA and parC for mutation detection. A 586 and a 265 base pair regions of DNA within the gyrA and parC gene were amplified for all the quinolone-resistant isolates The primers sequence used in this study are as follows; g y r A F -C G T C G C G TA C T T TA C G C C AT G A A C G , gyrA R-ATACCTTGCCGCGACCGGTACGG and p a r C F -T G TAT G C G AT G T C T G A A C T G , p a r C R-CTCAATAGCAGCTCGGAATA. [9] The reaction conditions were as follows; initial denaturation at 95°C for 2 min; 32 cycles of 95°C for 25 s, 52°C for 1 min and 72°C for 1.20 min and a final extension at 72°C for 7 min.
Denaturing gradient gel electrophoresis
To identify the mutation within the QRDR, the amplified products of the above gene were subjected to denaturing gradient gel electrophoresis (DGGE). The DGGE analysis was performed using a DCode™ Universal Mutation Detection System (Bio-Rad Laboratories, Hercules, CA, USA). PCR-DGGE amplicons were loaded in polyacrylamide gels (8% [wt/vol] acrylamide in 0.5X TAE buffer) with 40%-65% denaturant gradient being 7 M urea and 40% deionised formamide. The gels were electrophoresed at a constant voltage of 20 V for 15 min followed by 5 h 30 min at 200 V. After electrophoresis, gels were stained with ethidium bromide for 5 min and destained in distilled water for 20 min with agitation, after which their image the gel was placed on a UV transilluminator and visualised in Gel Doc EZ imager (Bio-Rad, USA).
rEsults
Screening results for seven quinolone resistance are illustrated in Table 1 . Among the collected isolates, 80 (83.3%) were resistant to nalidixic acid, 7 (7.2%) were intermediate and 9 (11%) were susceptible with MIC ≤ 0.05 μg/ml. Similarly, resistance rates to ciprofloxacin, norfloxacin, levofloxacin and ofloxacin were 80.2% (n = 77), 66.6% (n = 64), 23.9% (n = 23) and 50% (n = 48) with MIC 64, 256, 4 16 μg/ ml, respectively [ Table 1 ].
Multiplex PCR amplification with qnr and aac (6')-Ib-cr primers confirms the presence of aac (6')-Ib-cr genes in five isolates and no other gene could be found. All the resistant isolates were subjected for mutational analysis of QRDR region by DGGE. Amplification with oligonucleotide primers gyrA and parC amplified the expected 586 bp and 265 bp DNA fragments, respectively [ Figure 1 ].
The amplified products were subjected to DGGE. Analysis of the gel revealed four types (A-D) of band pattern of each gyrA and parC gene [ Figure 2 ]. To determine the contribution of mutation in QRDR which attributes FQ resistance, sequencing of gyrA and parC patterns were done. When the DNA sequence of the gyrA was compared with gyrA subunit of EC493/89, it revealed nucleotide differences at many positions. Pattern A was found to have 9-point mutations (EGYMU1), Pattern B with 13-point mutations (EGYMU2), Pattern C with 11-point mutations (EGYMU3) and Pattern D was found to have 10-point mutations (EGYMU4). Similarly, the isolates showing the four mutation patterns of parC were named as EPRMU1, EPRMU2, EPRMU3 and EPRMU4. Two transition mutations were common in all the isolates. Three insertion mutations of a single nucleotide were found between 166 th and 167 th base by T (starting with position 1 at the A of the start codon of gyrA) of gyrA pattern EGYMU1. At 181 th and 190 th base, deletion of single nucleotide A was observed in all gyrA pattern [ Figure 3 ]. Mutation in codons 83 and 87 in gyrA displays the most common alteration in clinical isolates. Transition mutation at codon 83 was a C-T that resulted in the substitution of leucine for serine in pattern A, B and D, but in pattern C (EGYMU3), transition mutation at codon 83 resulted in the substitution of glycine for serine. Another transition mutation was C-A at position 87, which resulted in an Asp87 Leu and Asp87 Asn. Twenty-one different types of mutation in gyrA were found amongst the isolates analysed. They were Trp56Met, Asn57Thr, Asn57His, Trp59Met, Asn60Thr, Asn60Asp, Lys61Gly, Lys61Ser, Ala62Thr, Ala62Pro, Tyr63Ser, Tyr63Ile, Lys64 Leu, Lys65Ile, Ser83 Leu, Ser83Gly, Val85Ala, Asp87Asn, Asp87 Leu, Arg91Tyr and Ser111Asn [ Figure 4 ].
Codons 74, 76, 77, 80, 82, 84, 89, 91, 105 and 107 showed alterations in the QRDR of the parC gene. The replacements were Tyr74 Leu, Pro76Phe, His77Arg, Ser80Ile, Ser80Arg, Cys82 Leu, Glu84Gly, Glu84 Lys, Met89 Leu, Gln91His, Asn105Thr and Gly107Ala. Mutations outside the QRDR were also observed during the study. A deletion of G at the 390 th base and a transversion of G-T at the 393 rd base in parC Based on the results of ERIC-PCR, isolates were grouped into eight different groups designated as 1-8 [ Figure 7 ]. The largest one belonged to cluster-4 and consisted of seven strains detected exclusively in UTI patients with length of hospital stay of 10-20 days. It is possible that this clone was spread among the UTI patients through contaminated catheters or contaminated urinary devices. Cefotaxime came up with moderate activity followed by imipenem and ceftazidime [ Table 2 ].
dIscussIon
Quinolones and FQs are the first-line drugs for the treatment of UTI and enteric infections for many years. For antibiotics such as FQs, chromosomal mutations play a more important role than horizontally transferable resistance genes in the development of clinically resistant pathogens. Resistance to FQs in bacteria is mainly mediated by spontaneous mutations in the QRDR of gyrA and parC genes, either gyrA or parC, or both genes, especially at the highly conserved residues (Ser-83 and Asp-87) of gyrA. [10] Here, we have determined how the abundance of chromosomal FQ-resistant mutations in the clinical E. coli isolates from hospital environment from India, a country with relatively high FQ consumption and resistance.
The widespread use of FQ antibiotics in clinical practice leads to the rapid development of resistant phenotype. One of the than ofloxacin and levofloxacin among the clinical isolates of E. coli. Similar findings have been reported in a previous study of E. coli isolates in Brazil. [11] Somewhat similar results were recorded in another study from Saudi Arabia [12] where the resistance rate to ciprofloxacin is quite high. This study also highlighted that mutation in the QRDR conferring resistance to FQ is associated with high MIC values. Molecular analysis by a combination of DGGE and DNA sequencing revealed various gyrA and parC sequence patterns. Accumulation of Ser83 Leu and Asp87Asn mutations in the gyrA gene of E. coli was common. Mutation in the gyrA and parC gene leading to FQ resistance in Enterobacteriaceae, [13] Pseudomonas aeruginosa [14] and Gram-positive [15] had been reported by many authors. Previous studies showed that a high level of resistance to FQs is associated with double mutations in GyrA and an additional mutation in ParC in E. coli. [16] We also found mutations in codon 83, 87 of gyrA and 80, 84 of parC along with some unique mutations.
To the best of our knowledge, this study also reported some unique mutation in codon 60, 64, 111 of GyrA; in addition, we identified silent mutations in codons 85, 86 and 91 in resistant strains. Mutations in parC were always found together with mutations in gyrA. This is due to topoisomerase IV being a secondary target for quinolones in E. coli. [17] However, mutations in parC play an important role in the formation of highly resistant strains. Except for one pattern A, amino acid change at codon most remarkable findings of this study was the widespread resistance to quinolones and FQs. This study has found that ciprofloxacin showed a higher number of resistant strains 80 in the QRDR of the ParC protein was observed in all the analysed strains. Unique mutation in codon 74 of ParC was also reported in this study. Whether the aminoacid substitution at codon 60, 64, 111 of GyrA associated with FQ resistance needs to be verified. Furthermore, the novel mutation outside the QRDR of parC should be studied thoroughly to detect the effect on drug target enzyme activity. These data indicate that high-level FQ resistance in E. coli involves the acquisition of mutations at multiple loci in the QRDRs and strategies should be adopted to limit the spread of resistance.
conclusIon
This study highlighted the predominance of FQ-resistant E. coli in this region due to mutation in the chromosomal region. Overall, the results of our study suggest that acquisition of mutations in gyrA and parC genes plays a significant role in the development of high-level resistance to quinolones in certain cluster lineages of E. coli. This study also poses a serious threat to the dissemination of this new point mutation. Findings of this study warrant a review of quinolone-based therapy in this region of the world and restriction in their over-the-counter availability and irrational use. 
